Announcing Benchling for Lab Automation: Harness the full power of your lab hardware Learn More

Meet our customers

“Since our founding, science has remained our central guiding principle. Benchling fits perfectly into this philosophy, providing us a flexible informatics platform that enables our scientists to focus on high-impact research and deliver life-transforming medicines.”
Nicholas Papadopoulos SVP R&D Operations, Regeneron

More than 170,000 scientists worldwide across pharma, biotech, and academia

  • Pfizer

    One of the world's largest pharmaceutical companies developing cutting-edge drugs in immunology, oncology, cardiology, and more.
  • Regeneron

    A leading biotechnology company using the power of science to bring new medicines to patients in need.
  • Eisai

    Eisai is a human health care (hhc) company seeking innovative solutions in disease prevention, treatment and care for the health and well-being of people worldwide.
  • Zoetis

    Zoetis is a global animal health company dedicated to supporting customers and their businesses in ever better ways, delivering medicines, vaccines, and diagnostic products.
  • Ginkgo

    Ginkgo Bioworks is designing custom organisms for customers across multiple markets, learning from nature to replace technology with biology.
  • Sorrento

    Sorrento Therapeutics is a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possible curable diseases.
  • CytomX

    CytomX is a clinical-stage biopharmaceutical company – intent on revolutionizing the way we treat cancer.
  • Bolt Threads

    Bolt Threads is bioengineering the next generation of fabrics and garments with their Microsilk and Mylo technologies.
  • Editas

    A leading genome editing company dedicated to treating patients with genetically defined diseases.
  • Rubius

    Rubius Therapeutics is realizing the power of red by creating red blood cells and transforming them into cellular medicines.
    Case Study
  • Incyte

    Investigating the immune-suppressive tumor microenvironment through both small and large molecule approaches that target diverse mechanisms.
  • Xencor

    Expanding the therapeutic boundaries of monoclonal antibody drugs with its XmAb antibody engineering platform.
  • Agenus

    Using the power of the immune system to develop a broad range of innovative therapeutic antibody and vaccine candidates against cancer.
    Case Study
  • New England Biolabs

    Recombinant and native enzyme reagents for life science research. Provides solutions supporting genome editing, synthetic biology and next-generation sequencing.
  • Adicet Bio

    Universal, off-the-shelf immune cell therapy for treatment of cancer and other diseases
    Case Study
  • uniQure

    Delivering on the promise of gene therapy, single treatments with potentially curative results.
  • Lung Biotechnology

    Lung Biotechnology's mission is to simplify and democratize the treatment of lung disease, using biotechnology to design therapies for PAH and other fatal lung diseases.
  • Mammoth Biosciences

    Mammoth Biosciences provides a CRISPR-based platform for disease detection across healthcare, agriculture, and other industries
  • Synlogic

    working at the intersection of biology and engineering, pioneering the application of synthetic biology to design living therapeutics programmed to treat disease in new ways
    Case Study
  • Genus

    Investigating the application of novel gene editing technologies towards bovine genetics.
  • Voyager Therapeutics

    Developing life-changing gene therapies with a focus on severe neurological diseases that lack safe and effective treatment options.
  • Zymergen

    Unlocking the power of biology to make strain optimization as reliable and predictable as other engineering processes.
    Case Study
  • Surrozen Therapeutics

    Surrozen is discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal properties of the body through specific control of the Wnt signaling pathway.
  • Caribou Biosciences

    Advancing new applications for CRISPR-Cas gene editing to help bring the promise this technology holds for patients and consumers to reality.
  • Arcturus Therapeutics

    An industry leader in the application of RNA technologies for the treatment of disease and improved quality of life.
    Case Study
  • IGM Biosciences

    IGM is pioneering the development of the IgM class of antibodies as therapeutic treatments for human disease.
  • Translate Bio

    Translate Bio is an mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.
  • Diassess

    Diassess's product detects the genetic information of disease pathogens using nucleic acid amplification to provide a highly accurate diagnosis.
  • Inhibrx

    Enabling fit-for-function biotherapeutics that optimally interface with the biology of each target antigen, focus immune activation, and mediate enhanced signaling.
  • Jnana Therapeutics

    Jnana is pushing the frontiers of knowledge and technology to decipher the language of cellular metabolite communication and unlock SLC transporters as a therapeutic target class.
  • Tenaya Therapeutics

    Tenaya is addressing heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle.
  • Asimov

    Asimov strives to enable biotechnologies with global benefit by combining synthetic biology and computer science.
  • Dragonfly Therapeutics

    Developing novel first-in-class therapeutics targeted at Natural Killer cells and other cells of the innate immune system.
  • Adimab

    A premier human antibody discovery and optimization platform defined by speed, diversity, and quality.
  • Horizon

    A leading gene editing company that designs and engineers genetically modified cells for clinical applications.
  • Synpromics

    Improving human health by enabling safer, more effective cell and gene medicines through proprietary genomics, bioinformatics and intelligent data driven design.
  • Ligand Pharmaceuticals

    Ligand has one of the largest and most diverse portfolios in the pharmaceutical industry. Currently approved portfolio drugs include those that treat cancer, osteoporosis, and fungal infections.
  • ABL Bio

    ABL Bio is one of the world's leading biotech research companies focusing on the development of therapeutic drugs for immuno-oncology & neurodegenerative diseases.
  • Obsidian Therapeutics

    Building cell therapies with pharmacologic operating systems to provide treating physicians with precise and dynamic control of engineered cells in patients.
  • enGene

    enGene has developed a robust non-viral gene-therapy platform to transport DNA sequences across mucosal barriers.
  • Freenome

    Making cancer screening and diagnostics as accurate and accessible as possible, through a fusion of machine learning, biology and computer science.
  • MiNA Therapeutics

    Harnessing the innate mechanism of gene activation, MiNA Therapeutics' platform enables the development of new medicines that restore normal function to patients’' cells.
  • Antheia

    Providing a stable and cost-competitive supply of plant-based medicines and to transform the discovery, manufacture, and distribution of medicines.
  • Atreca

    Atreca focuses on the immune responses of patients to discover and develop novel immunotherapies.
  • Neucyte

    NeuCyte is an innovative biotechnology company focused on CNS drug discovery. NeuCyte has developed an in vitro platform for neurotoxicity assessment, disease modeling, and more.
  • Samplix

    Samplix is a biotechnology company that has developed a proprietary technology for single molecule sample preparation.
  • Aether

    Aether Biomachines is repurposing enzymes to reinvent previously discovered compounds and create novel compounds.
  • Recursion Pharmaceuticals

    Discovering transformative new treatments by leveraging the speed of automation with the intelligence of computers.
  • Harpoon Therapeutics

    Leveraging a platform focused on T cell engagement to discover and develop novel biologics for the treatment of cancer and other diseases
  • Maverick Therapeutics

    Redirected T cell therapeutics designed to deliver potent activity with increased tumor specificity and reduced toxicity.
  • Scenic Biotech

    Scenic is pioneering genetic modifies for drug discovery to build a pipeline of breakthrough products.
  • Carisma Therapeutics

    Carisma Therapeutics is pioneering CAR macrophage immunotherapy to target solid tumors.
  • LogicBio Therapeutics

    Harnessing the body's natural DNA repair process to provide precise, stable, and durable therapies to patients with serious genetic diseases.
  • Finch

    Developing and delivering innovative therapies that harness the human gut microbiome.
  • Inari

    Developing and delivering innovative therapies that harness the human gut microbiome.
  • AgBiome

    AgBiome develops innovative, cutting-edge solutions using new knowledge of the plant-associated microbiome to create novel products.
  • Cue Biopharma

    Cue Biopharma is an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system.
  • Lumen Bioscience

    Lumen Bioscience makes oral antibody therapeutics.
  • EnginZyme

    EnginZyme engineers cost-competitive biocatalytic solutions fast than ever before, using their universal system for enzyme immobilization.
  • Insitro

    insitro will integrate cutting-edge machine learning techniques with the innovations that have occurred in life sciences that enable the creation of the large, high-quality data sets.
  • Hibercell

    HiberCell is developing first-in-class therapeutics that target dormant disseminated tumor cells from solid and liquid cancers to the prevent or delay the recurrence of cancer.
  • Rarecyte

    RareCyte is enabling next-generation analysis of rare cells with an open and end-to-end platform that supports clinical trials worldwide.
  • TScan Therapeutics

    TScan is harnessing novel T cell systems to extend the promise of immunotherapy.
  • Kymera Therapeutics

    Kymera Therapeutics is pioneering a new therapeutic modality and platform with the potential to transform drug discovery and deliver breakthrough medicines for previously untreatable diseases.
  • GeneQuine

    GeneQuine Biotherapeutics GmbH develops novel therapies for osteoarthritis, a degenerative joint disease with high unmet medical need.
  • Cedilla Therapeutics

    Cedilla is harnessing intrinsic protein stability mechanisms to broaden the reach of small molecule therapeutics to work on diseases caused by protein dysregulation.
  • Admirx

    Admirx is a preclinical-stage company developing anti-complement therapies to treat life threatening auto-immune and inflammatory diseases.
  • Cygnal Therapeutics

    Cygnal Therapeutics is developing drugs to manipulate exoneural biology for the treatment of cancer, immunological diseases, and regenerative processes.
  • Invaio Sciences

    Invaio Sciences is a transformative early-stage startup developing a platform to control the fitness and behavior of pests and target insects in a targeted, sustainable, and natural way.
  • enEvolv

    Engineering microorganisms to produce valuable bio-based products from renewable feedstocks.
  • Orum

    Developing next-generation therapeutic antibodies to directly target cytosolic proteins associated with many human diseases that have been previously considered untreatable.
  • eGenesis

    Making xenotransplantation a routine medical procedure for the delivery of safe & effective human transplantable cells, tissues & organs.
  • Verseau

    Transforming immunotherapy.
  • Hexagon Bio

    Mining massive amounts of genomic data from fungal genomes to identify novel drugs for diseases with unmet needs.
  • Pandion Therapeutics

    Shifting the paradigm from systemic immunosuppression to localized immunomodulation with the next generation of targeted therapeutics.
  • Eligo Bioscience

    Developing a new class of targeted biotherapeutic agents to selectively intervene on the microbiome.
  • Senti Biosciences

    Leveraging expertise in cell engineering and biological programming to build the future of gene and cell based therapies.
  • Ribometrics

    Discovering small molecule drugs that target functional 3D RNA structures to treat human diseases.

Join over 170,000 scientists using
Benchling to power life science R&D